Trial · NCT02497287
Results by group47
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 47
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | Intranasal Esketamine + Oral Antidepressant | 90.1 | Percentage of participants | ||
| Percentage of Participants With Cystitis, Urinary Tract Infections, Renal and Urinary Tract Symptoms, Renal and Urinary Disorders | Intranasal Esketamine + Oral Antidepressant | Cystitis | 0.6 | Percentage of participants | |
| Percentage of Participants With Cystitis, Urinary Tract Infections, Renal and Urinary Tract Symptoms, Renal and Urinary Disorders | Intranasal Esketamine + Oral Antidepressant | Urinary tract infections | 8.1 | Percentage of participants | |
| Percentage of Participants With Cystitis, Urinary Tract Infections, Renal and Urinary Tract Symptoms, Renal and Urinary Disorders | Intranasal Esketamine + Oral Antidepressant | Renal and urinary disorders | 10.5 | Percentage of participants | |
| Percentage of Participants With Cystitis, Urinary Tract Infections, Renal and Urinary Tract Symptoms, Renal and Urinary Disorders | Intranasal Esketamine + Oral Antidepressant | Renal and urinary tract symptoms | 17.0 | Percentage of participants | |
| Change From Baseline in Cognitive Test Battery: Detection Test (DET) Score | Intranasal Esketamine + Oral Antidepressant | -0.0028 | Standard Deviation 0.12744 | log10 msec | |
| Change From Baseline in Cognitive Test Battery: Identification Test (IDN) Score | Intranasal Esketamine + Oral Antidepressant | -0.0083 | Standard Deviation 0.09656 | log10 msec | |
| Change From Baseline in Cognitive Test Battery: One Card Learning Test (OCL) Score | Intranasal Esketamine + Oral Antidepressant | 0.0502 | Standard Deviation 0.13149 | Arcsine ([sqrt] of proportion of [CR]) | |
| Change From Baseline in Cognitive Test Battery: One Back Test (ONB) Score | Intranasal Esketamine + Oral Antidepressant | 0.0177 | Standard Deviation 0.10026 | log10 msec | |
| Change From Baseline in Cognitive Test Battery: Groton Maze Learning Test (GMLT) Score | Intranasal Esketamine + Oral Antidepressant | 6.9 | Standard Deviation 25.36 | Number of Errors | |
| Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Total Recall | Intranasal Esketamine + Oral Antidepressant | 2.8 | Standard Deviation 4.74 | Number correct | |
| Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Delayed Recall | Intranasal Esketamine + Oral Antidepressant | 0.8 | Standard Deviation 2.31 | Number correct | |
| Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Number of Words Recalled | Intranasal Esketamine + Oral Antidepressant | 0.3 | Standard Deviation 2.83 | Number of words recalled | |
| Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score: Recognition Discrimination Index | Intranasal Esketamine + Oral Antidepressant | 0.5 | Standard Deviation 3.16 | Number of words | |
| Change From Baseline to Endpoint in Montgomery Asberg Depression Rating Scale (MADRS) Total Score During Induction (IND) Phase | Intranasal Esketamine + Oral Antidepressant | -16.4 | Standard Deviation 8.76 | Units on a Scale | |
| Change From Baseline to Endpoint in MADRS Total Score During Optimization/Maintenance (OP/MA) Phase | Intranasal Esketamine + Oral Antidepressant | 0.3 | Standard Deviation 8.12 | Units on a Scale | |
| Change From Baseline to Endpoint in Patient Health Questionnaire - 9 (PHQ-9) Total Score During IND Phase | Intranasal Esketamine + Oral Antidepressant | -8.9 | Standard Deviation 6.67 | Unit on a Scale | |
| Change From Baseline to Endpoint in PHQ-9 Total Score During OP/MA Phase | Intranasal Esketamine + Oral Antidepressant | -0.2 | Standard Deviation 5.65 | Units on a Scale | |
| Change From Baseline to Endpoint in Clinical Global Impression of Severity (CGI-S) Scale Score During IND Phase | Intranasal Esketamine + Oral Antidepressant | -2.0 | Full Range -6 to 2 | Units on a Scale | |
| Change From Baseline to Endpoint in CGI-S Scale Score During OP/MA Phase | Intranasal Esketamine + Oral Antidepressant | 0.0 | Full Range -3 to 4 | Units on a Scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02497287/results